Cancer Treatment Before and After Physician-Pharmacy Integration
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.12998 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Genevieve P Kanter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Sol Price School of Public Policy, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Integration of pharmacies with physician practices, also known as medically integrated dispensing, is increasing in oncology. However, little is known about how this integration affects drug use, expenditures, medication adherence, or time to treatment initiation.
Objective
To examine the association of physician-pharmacy integration with oral oncology drug expenditures, use, and patient-centered measures. Design, Setting, and Participants This cohort study used claims data from a large commercial insurer in the US to analyze changes in outcome measures among patients treated by pharmacy-integrating vs nonintegrating community oncologists in 14 states between January 1, 2011, and December 31, 2019. Commercially insured patients were aged 18 to 64 years with 1 of the following advanced-stage diagnoses: breast cancer, colorectal cancer, kidney cancer, lung cancer, melanoma, or prostate cancer. Data analysis was conducted from May 2023 to March 2024. Exposure Treatment by a pharmacy-integrating oncologist, ascertained by the presence of an on-site pharmacy or nonpharmacy dispensing site. Main Outcomes and Measures Oral, intravenous (IV), total, and out-of-pocket drug expenditures for a 6-month episode of care; share of patients prescribed oral drugs; days’ supply of oral drugs; medication adherence measured by proportion of days covered; and time to treatment initiation. The association between an oncologist’s pharmacy integration and each outcome of interest was estimated using the difference-in-differences estimator.
Results
Between 2012 and 2019, 3159 oncologists (745 females [27.1%], 2002 males [72.9%]) treated 23 968 patients (66.4% female; 53.4% aged 55-64 years). Of the 3159 oncologists, 578 (18.3%) worked in practices that integrated with pharmacies (with a low rate in 2011 of 0% and a high rate in 2019 of 31.5%). In the full sample (including all cancer sites), after physician-pharmacy integration, no significant changes were found in oral drug expenditures, IV drug expenditures, or total drug expenditures. There was, however, an increase in days’ supply of oral drugs (5.96 days; 95% CI, 0.64-11.28 days; P = .001). There were no significant changes in out-of-pocket expenditures, medication adherence, or time to treatment initiation of oral drugs. In the breast cancer sample, there was an increase in oral drug expenditures ($244; 95% CI, $41-$446; P = .02) and a decrease in IV drug expenditures (–$4187; 95% CI, –$8293 to –$80; P = .05). Conclusions and Relevance Results of this cohort study indicated that the integration of oncology practices with pharmacies was not associated with significant changes in expenditures or clear patient-centered benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy and Management, Sol Price School of Public Policy, University of Southern California, Los Angeles.
- Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
- Elevance Health Inc, Indianapolis, Indiana.
- Carelon Medical Benefits Management, Chicago, Illinois.
- Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Zitieren
APA
Kanter, G. P., Ozluk, P., Chi, W., Fisch, M. J., Debono, D., Parikh, R. B., Jacobson, M., Bekelman, J. E., & DeVries, A. (2024). Cancer Treatment Before and After Physician-Pharmacy Integration. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.12998
Vancouver
Kanter GP, Ozluk P, Chi W, Fisch MJ, Debono D, Parikh RB, et al. Cancer Treatment Before and After Physician-Pharmacy Integration. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.12998
BibTeX
@article{Kanter2024,
author = {Kanter, Genevieve P and Ozluk, Pelin and Chi, Winnie and Fisch, Michael J and Debono, David and Parikh, Ravi B and Jacobson, Mireille and Bekelman, Justin E and DeVries, Andrea},
title = {Cancer Treatment Before and After Physician-Pharmacy Integration},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.12998}
}
EUVIMED